Learning Center

Ursodeoxycholate modulates bile flow and bile salt pool independently from the cystic fibrosis transmembrane regulator (CFTR) in mice.

Our results in mice...When extrapolated to the human situation...might imply that UDCA treatment results both in CF and in non-CF individuals in increased choleresis, reduced bile salt synthesis, and a more hydrophilic bile salt pool.